Matches in Wikidata for { <http://www.wikidata.org/entity/Q90835085> ?p ?o ?g. }
Showing items 1 to 42 of
42
with 100 items per page.
- Q90835085 description "artículu científicu espublizáu en marzu de 2020" @default.
- Q90835085 description "im März 2020 veröffentlichter wissenschaftlicher Artikel" @default.
- Q90835085 description "scientific article published on 31 March 2020" @default.
- Q90835085 description "wetenschappelijk artikel" @default.
- Q90835085 description "наукова стаття, опублікована 31 березня 2020" @default.
- Q90835085 name "New thrombopoietin receptor agonist (Lusutrombopag) is more effective in impaired renal function patients with chronic liver disease" @default.
- Q90835085 name "New thrombopoietin receptor agonist (Lusutrombopag) is more effective in impaired renal function patients with chronic liver disease" @default.
- Q90835085 type Item @default.
- Q90835085 label "New thrombopoietin receptor agonist (Lusutrombopag) is more effective in impaired renal function patients with chronic liver disease" @default.
- Q90835085 label "New thrombopoietin receptor agonist (Lusutrombopag) is more effective in impaired renal function patients with chronic liver disease" @default.
- Q90835085 prefLabel "New thrombopoietin receptor agonist (Lusutrombopag) is more effective in impaired renal function patients with chronic liver disease" @default.
- Q90835085 prefLabel "New thrombopoietin receptor agonist (Lusutrombopag) is more effective in impaired renal function patients with chronic liver disease" @default.
- Q90835085 P1433 Q90835085-E5FFB84A-A67B-4EEC-A09F-BF953BFB95AD @default.
- Q90835085 P1476 Q90835085-7688CF99-7370-42B5-8408-0A898F46980E @default.
- Q90835085 P2093 Q90835085-36AD7AFA-B1BE-4F5D-9A66-1A8E5CDD53AB @default.
- Q90835085 P2093 Q90835085-4018DC2E-E1A1-433E-8A95-2F8A344989EE @default.
- Q90835085 P2093 Q90835085-666D8D61-1EE3-4D96-80F3-194B93BF03E6 @default.
- Q90835085 P2093 Q90835085-704AB2C5-2243-41B7-8487-7BC16A6C9A78 @default.
- Q90835085 P2093 Q90835085-AA7F382F-83B5-4BBF-8805-32E9B06F05CA @default.
- Q90835085 P2093 Q90835085-C9E5DC08-CCDB-4475-BF2E-2EEA54B674D2 @default.
- Q90835085 P2093 Q90835085-E1CFE5F0-91AD-4266-B106-CAFC97D44BDE @default.
- Q90835085 P31 Q90835085-0A1CD19D-1D85-45F0-AEF4-5D34AFAF2D69 @default.
- Q90835085 P356 Q90835085-4B0C110A-F24C-4B91-8503-689A77A9C1A5 @default.
- Q90835085 P577 Q90835085-446E6311-1A16-48C1-A437-11A4D4A02673 @default.
- Q90835085 P698 Q90835085-D3A91599-F530-4352-9775-ADC0B3F64FF2 @default.
- Q90835085 P921 Q90835085-78ADAD9A-3425-4782-A62A-1BAFAD8B32ED @default.
- Q90835085 P356 JNMS.JNMS.2020_87-603 @default.
- Q90835085 P698 32238734 @default.
- Q90835085 P1433 Q15753386 @default.
- Q90835085 P1476 "New thrombopoietin receptor agonist (Lusutrombopag) is more effective in impaired renal function patients with chronic liver disease" @default.
- Q90835085 P2093 "Hirohito Takeuchi" @default.
- Q90835085 P2093 "Katsutoshi Sugimoto" @default.
- Q90835085 P2093 "Masakazu Abe" @default.
- Q90835085 P2093 "Takao Itoi" @default.
- Q90835085 P2093 "Yoshihiro Furuichi" @default.
- Q90835085 P2093 "Yoshitaka Kasai" @default.
- Q90835085 P2093 "Yu Yoshimasu" @default.
- Q90835085 P31 Q13442814 @default.
- Q90835085 P356 "10.1272/JNMS.JNMS.2020_87-603" @default.
- Q90835085 P577 "2020-03-31T00:00:00Z" @default.
- Q90835085 P698 "32238734" @default.
- Q90835085 P921 Q5113984 @default.